Saturday, June 29, 2024
HomeTagsExelixis

Exelixis

Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022

Exelixis, Inc. (Nasdaq: EXEL) today announced results for cabozantinib (CABOMETYX®) in combination with immunotherapies in patients with advanced colorectal cancer, including encouraging data from...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics